Stryker Gets FDA 510(k) Clearance for OptaBlate System

Dow Jones
May 20
 

By Chris Wack

 

Stryker said Monday that its OptaBlate basivertebral nerve ablation system received 510(k) clearance from the Food and Drug Administration.

The medical technology company said its OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting vertebrogenic pain relief.

Stryker said the OptaBlate system achieves at least a 1-centimeter lesion in seven minutes, and its microinfusion technology, which keeps the zone hydrated, reduces impedance errors and prevents charring.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

May 19, 2025 13:19 ET (17:19 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10